Abstract Details

Title Disability in the first 10 years of Relapse-onset MS is principally a product of relapses with incomplete recovery

Topic Multiple Sclerosis

Presentation(s) P4 - (-)

Poster/Presentation
Number 399

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Wisam Elmalik, MD (DENT Neurological institute) PRESENTER	No disclosure on file
Thomas F. Scott, MD (Allegheny Neurological Assoc)	Dr. Scott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Scott has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme. Dr. Scott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Serono. Dr. Scott has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Scott has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Dr. Scott has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Scott has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genzyme. Dr. Scott has received research support from Biogen. Dr. Scott has received research support from Novartis.
Edward J. Gettings, DO (Temple University)	Dr. Gettings has nothing to disclose.
Chris Hackett, MA	Mr. Hackett has nothing to disclose.
	No disclosure on file